SLCO1C1
ENSG00000139155
Target class
Transporter
Chromosome
12
- Chemical probe available
- No
- Target name
- SLCO1C1
- Gene name
- Solute carrier organic anion transporter family member 1C1
- Gene symbol
- SLCO1C1
- Previous gene symbols
- SLC21A14
- Protein name
- Solute carrier organic anion transporter family member 1C1 (Organic anion transporter 1C1) (OATP1C1) (Organic anion transporter F) (OATP-F) (Organic anion transporter polypeptide-related protein 5) (OAT-RP-5) (OATP-RP5) (Organic anion-transporting polypeptide 14) (OATP-14) (Solute carrier family 21 member 14) (Thyroxine transporter)
- OATP-F
- OATP1C1
- OATP1
- Gene biotype
- Protein coding
- Gene family
- Solute carrier organic anion transporter family
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 16
- Highest tissue expression
- 15.77
- Tissue specificity (Gini)
- 0.764
- Tissue specificity (tau)
- 0.872
- KEGG gene identifiers
- hsa:53919
- Reactome pathways
- R-HSA-879518
- Protein interaction confidence
- 0.799167
- Protein interaction partners
- 6
- End position
- 20753386
- Start position
- 20695332
- Chromosome
- 12
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Note=Expressed in both luminal and abluminal membranes of brain capillary endothelial cells. Localized to the apical membrane and basal surfaces of choroid plexus. .
- PubMed 12351693
- PubMed 18687783
- Tissue specificity (tau)
- 0.872052
- Expression inequality (Gini)
- 0.764393
Expression in transcripts per million
- Brain - Caudate (basal ganglia)
- 15.77
- Brain - Anterior cingulate cortex (BA24)
- 13.57
- Brain - Frontal Cortex (BA9)
- 12.65
- Brain - Nucleus accumbens (basal ganglia)
- 12.52
- Brain - Cortex
- 12.47
Expression in transcripts per million
- Brain - Caudate (basal ganglia)15.77
- Brain - Anterior cingulate cortex (BA24)13.57
- Brain - Frontal Cortex (BA9)12.65
- Brain - Nucleus accumbens (basal ganglia)12.52
- Brain - Cortex12.47
- Brain - Putamen (basal ganglia)12.29
- Brain - Amygdala10.41
- Brain - Hippocampus6.42
- Brain - Substantia nigra3.58
- Brain - Hypothalamus2.93
- Nerve - Tibial2.64
- Testis2.15
- Brain - Spinal cord (cervical c-1)1.85
- Brain - Cerebellum1.61
- Thyroid1.6
- Brain - Cerebellar Hemisphere1.12
- Adipose - Subcutaneous0.77
- Breast - Mammary Tissue0.71
- Adipose - Visceral (Omentum)0.68
- Artery - Coronary0.67
- Pituitary0.46
- Artery - Aorta0.42
- Artery - Tibial0.38
- Esophagus - Muscularis0.36
- Esophagus - Gastroesophageal Junction0.36
And 29 more, listed on the interactive page.
- GO:0055085
- GO:0070327
- GO:2000611
- GO:0005886
- GO:0016323
- GO:0005515
- GO:0015349
- GO:0022857
Related records
Trials (65)
- 10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors
- A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)
- A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.
- A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults
- A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)
- A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood
- A Study of Baricitinib and Probenecid in Healthy Participants
- A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease
- A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants
- A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
- A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers
- A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants
- A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects
- A Study to Evaluate the Efficacy of PanCytoVir™ for the Treatment of Non-Hospitalized Patients With COVID-19 Infection
- A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients
- A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
- A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
- Addition of Probenecid to Penicillin-V Therapy
- An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS
- Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers